GlassScriptPhysician profile
Sarah M Deuser
NPI 1962674259
$8,986.18
in general payments reported to CMS, 2019-2025
24 companies · $2,555 in 2025
The $2,555 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $874 · 2022: $1,555 · 2023: $1,266 · 2024: $2,737 · 2025: $2,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,419 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,418.92 |
| Education | $138.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,478.39 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,083.93 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| E.R. Squibb & Sons, L.L.C. | $745.89 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $698.12 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $684.65 | 2021-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $651.27 | 2021-2025 | |
| Lundbeck LLC | $530.09 | 2021-2025 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $492.27 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $475.43 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $452.99 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $376.09 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $367.26 | 2021-2023 | Nuplazid |
| Axsome Therapeutics, INC. | $358.11 | 2023-2025 | Auvelity |
| Indivior INC. | $117.02 | 2022-2024 | Perseris, Sublocade |
| Janssen Scientific Affairs, LLC | $102.45 | 2024 | Invega Trinza, Spravato |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $84.70 | 2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $72.03 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $65.90 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $59.72 | 2023-2025 | Trintellix |
| Coherus Oncology, INC. | $24.03 | 2022 | |
| Neuronetics, INC. | $21.60 | 2025 | Neurostar Tms Therapy System |
| Eisai INC. | $18.43 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.82 | 2024 | |
| Noven Therapeutics, LLC | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Deuser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.